NDLI: Age and acute myeloid leukemia

Content Provider	PubMed Central
Author	Appelbaum, Frederick R. Holly, Gundacker Head, David R. Slovak, Marilyn L. Willman, Cheryl L. Godwin, John E. Anderson, Jeanne E. Petersdorf, Stephen H.
Copyright Year	2006
Abstract	We conducted a retrospective analysis of 968 adults with acute myeloid leukemia (AML) on 5 recent Southwest Oncology Group trials to understand how the nature of AML changes with age. Older study patients with AML presented with poorer performance status, lower white blood cell counts, and a lower percentage of marrow blasts. Multidrug resistance was found in 33% of AMLs in patients younger than age 56 compared with 57% in patients older than 75. The percentage of patients with favorable cytogenetics dropped from 17% in those younger than age 56 to 4% in those older than 75. In contrast, the proportion of patients with unfavorable cytogenetics increased from 35% in those younger than age 56 to 51% in patients older than 75. Particularly striking were the increases in abnormalities of chromosomes 5, 7, and 17 among the elderly. The increased incidence of unfavorable cytogenetics contributed to their poorer outcome, and, within each cytogenetic risk group, treatment outcome deteriorated markedly with age. Finally, the combination of a poor performance status and advanced age identified a group of patients with a very high likelihood of dying within 30 days of initiating induction therapy. The distinct biology and clinical responses seen argue for age-specific assessments when evaluating therapies for AML.
Related Links	http://dx.doi.org/10.1182/blood-2005-09-3724
Ending Page	3485
Page Count	5
Starting Page	3481
File Format	PDF
ISSN	00064971
e-ISSN	15280020
Journal	Blood
Issue Number	9
Volume Number	107
Language	English
Publisher	The American Society of Hematology
Publisher Date	2006-05-01
Access Restriction	Open
Rights Holder	The American Society of Hematology
Subject Keyword	Immunology Cell Biology Biochemistry Hematology Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Cell Biology Hematology Biochemistry Immunology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Gefitinib induces myeloid differentiation of acute myeloid leukemia

MicroRNA 29b functions in acute myeloid leukemia

How I treat pediatric acute myeloid leukemia

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment

Age and acute myeloid leukemia

Similar Documents

Gefitinib induces myeloid differentiation of acute myeloid leukemia

MicroRNA 29b functions in acute myeloid leukemia

How I treat pediatric acute myeloid leukemia

Intensive chemotherapy does not benefit most older patients (age 70 years or older) with acute myeloid leukemia

The JAK2V617F activating mutation occurs in chronic myelomonocytic leukemia and acute myeloid leukemia, but not in acute lymphoblastic leukemia or chronic lymphocytic leukemia

Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

Requirement for CDK6 in MLL-rearranged acute myeloid leukemia

Prognostic impact and targeting of CRM1 in acute myeloid leukemia

Acute myeloid leukemia creates an arginase-dependent immunosuppressive microenvironment

Age and acute myeloid leukemia